Novartishas acquired an investigational cytomegalovirus (CMV) vaccine programme from the US-based vaccine developer AlphaVax for $20 million.
Novartishas acquired an investigational cytomegalovirus (CMV) vaccine programme from the US-based vaccine developer AlphaVax for $20 million.
The acquisition of the CMV programme adds to Novartis's early-stage vaccine pipeline that focuses on meningococcal infections and other hospital...
Create an account to read this article
Already a subscriber?
Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.
